In a bid to meet escalating demand for its obesity drugs, pharmaceutical behemoth, Eli Lilly & Co. (NYSE:LLY) has funneled $800 million into its Irish operations to ramp up the production of its blockbuster drugs, Mounjaro and Zepbound. What Happened: The investment is aimed at ensuring a steady supply of the drugs, which have been grappling with shortages since 2022. The facility, situated near the town of Kinsale in County Cork, Ireland, will manufacture tirzepatide, the key ingredient in these injectable medicines, Bloomberg reported on Thursday. The decision comes in the wake of the U.S. g…